Whoop

Whoop closed its Series G on March 31, 2026 — $575M at a $10.1B valuation, nearly triple its prior $3.6B mark — with a cap table that doubles as a strategy document: Collaborative Fund leading, sovereign scale from QIA and Mubadala, and, most tellingly, Abbott and the Mayo Clinic as strategic investors, pointing at CGM integration and clinical-grade ambitions. The operating numbers justify the enthusiasm: more than 2.5 million members, subscriptions up 103% year-over-year, cash-flow positive in 2025, and reported bookings run-rate around $1.1B — proof that the subscription-hardware model Whoop pioneered generates the recurring-revenue economics that hardware peers like Garmin are valued without. The May 2025 launch of WHOOP 5.0 and the medical-grade WHOOP MG (ECG, blood-pressure insights, 14-day battery) pushed the platform beyond athletic recovery into cardiovascular health, and Whoop then won the fight that defines the category's frontier: after the FDA's July 2025 warning letter over Blood Pressure Insights, the agency updated its wellness guidance in January 2026 to accommodate exactly such features and formally dropped the letter in June 2026 following modest feature adjustments — a regulatory precedent Whoop's slower rivals now benefit from second. With Whoop Coach embedding LLM coaching into billions of hours of physiological data, global expansion funded, and management signaling the Series G as the final private round before an IPO, Whoop enters the public-market window as the category's premium subscription franchise with medical-grade optionality — the closest thing wearables has to a platform company that owns its recurring revenue.

At $10.1B, Whoop is valued at roughly a quarter of Garmin — a company with several billion dollars of annual revenue, fat profits, and a diversified portfolio — on the strength of a single screenless band whose core metrics (sleep, HRV, recovery, strain) are now bundled features on every Apple Watch, Galaxy Watch, Garmin, and $299 Oura ring, most without Whoop's recurring toll. The subscription model is the vulnerability as much as the asset: May 2025's upgrade-policy fiasco — members discovering the promised free hardware upgrade had quietly become a $49-79 fee or a 12-month extension, "Whoopgate" trending until the company reversed course within days and issued refunds — revealed how fragile the social contract underneath subscription hardware is, and how quickly the community that built the brand can turn. The FDA episode reads two ways: Whoop won, but only after a formal warning letter, a public standoff, and feature modifications, and its stated appetite for pushing medical-adjacent claims ("we won't let regulatory overreach dictate...") guarantees future collisions as it markets blood pressure and ECG to a mass audience. Growth math is the deeper question: subscriptions doubling in 2025 came partly from the 5.0 upgrade supercycle and international launches that don't repeat annually, churn in subscription wearables is structurally high once novelty fades, and Abbott's involvement cuts both ways — the CGM giant has its own consumer ambitions (Lingo) and a history of keeping partners optional. The Series G's sovereign-wealth composition at a tripled valuation prices flawless IPO execution; any public-market comp against Garmin's economics, or a soft quarter of net adds, and late money at $10.1B owns venture risk at platform pricing.